| Daiichi Sankyo to Launch Innovator Products in Mexico through Ranbaxy
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Event - Victoza approval could pave the way for Byetta LAR approval
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
|
(Eli Lilly)
|
(Invalid Date)
|
| BMS and Lilly settle scrap but they could be glad of company
|
(Eli Lilly)
|
(Invalid Date)
|
| Victoza's victory could be short lived
|
(Novo Nordisk)
|
(Invalid Date)
|
| Transition Therapeutics Announces Results of a Phase 2 Study of TT-223 in Type 2 Diabetes Patients
|
(Transition Therapeutics)
|
(Invalid Date)
|
| Shionogi Receives Marketing and Manufacturing Approval of an Antidepressant Drug, “Cymbalta® Capsules 20mg and 30mg”
|
(Shionogi)
|
(Invalid Date)
|
| Which of 2010's launches will be future blockbusters?
|
(Amgen)
|
(Invalid Date)
|
| New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
|
(Eli Lilly)
|
(Invalid Date)
|
| New Analysis Showed Effient® Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| MedImmune Replies to FDA Complete Response Letter on Motavizumab
|
(AstraZeneca)
|
(Invalid Date)
|
| Glenmark Generics Ltd Receives Tentative Approval from USFDA for Pramipexole Dihydrochloride Tablets and Atomoxetine Hydrochloride Capsules
|
(Glenmark Pharmaceuticals)
|
(Invalid Date)
|
| OSI's Tarceva miss is Lilly's gain
|
(OSI Pharmaceuticals)
|
(Invalid Date)
|
| FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
|
(Eli Lilly)
|
(Invalid Date)
|
| FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
|
(Eli Lilly)
|
(Invalid Date)
|
| Launch of Once-daily-available “Adcirca® Tablets 20mg” for the Treatment of Pulmonary Arterial Hypertension
|
(Nippon Shinyaku)
|
(Invalid Date)
|
| Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
|
(Eli Lilly)
|
(Invalid Date)
|
| Lilly Announces the First 300-unit Vial of Insulin
|
(Eli Lilly)
|
(Invalid Date)
|
| FDA Approves Lilly's Zyprexa for Two Adolescent Indications
|
(Eli Lilly)
|
(Invalid Date)
|
| FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
|
(Eli Lilly)
|
(Invalid Date)
|
| Sun Pharma Announces USFDA Tentative Approval for Generic Strattera® Capsules
|
(Sun Pharmaceutical Industries)
|
(Invalid Date)
|
| Second Erbitux rebuff slams door on lung cancer approval in Europe
|
(Merck KGaA)
|
(Invalid Date)
|
| Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
|
(Raptor Pharmaceuticals)
|
(Invalid Date)
|
| Merck KGaA: CHMP Opinion for Erbitux in Advanced Non-Small Cell Lung Cancer
|
(Merck KGaA)
|
(Invalid Date)
|
| Therapeutic focus - Addex could be leading the mGluR pack
|
(Addex Pharmaceuticals)
|
(Invalid Date)
|
| Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
|
(Eli Lilly)
|
(Invalid Date)
|
| Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
|
(Eli Lilly)
|
(Invalid Date)
|
| Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
|
(Raptor Pharmaceuticals)
|
(Invalid Date)
|
| Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
|
(Eli Lilly)
|
(Invalid Date)
|
| Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen
|
(Johnson & Johnson)
|
(Invalid Date)
|
| More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens
|
(Vertex Pharmaceuticals)
|
(Invalid Date)
|
| Event – Taspoglutide data adds pressure on Victoza
|
(Ipsen)
|
(Invalid Date)
|
| BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
|
(Eli Lilly)
|
(Invalid Date)
|
| Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment
|
(Vertex Pharmaceuticals)
|
(Invalid Date)
|
| Corcept puts itself on the map with fundraising
|
(Corcept Therapeutics)
|
(Invalid Date)
|
| Pfizer halts trial of industry's most advanced IGF-1R antibody
|
(Pfizer)
|
(Invalid Date)
|
| Zelos Therapeutics Initiates Clinical Study of First US Injectable Equivalent to Forteo® (teriparatide)
|
(Zelos Therapeutics)
|
(Invalid Date)
|
| The Erbitux and Vectibix battle ready to begin in earnest
|
(Amgen)
|
(Invalid Date)
|
| Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting
|
(Vertex Pharmaceuticals)
|
(Invalid Date)
|
| Erbitux Significantly Increases Survival in 1st-Line Metastatic Colorectal Cancer Patients
|
(Merck KGaA)
|
(Invalid Date)
|
| Initial COIN Study Results Presented at European Oncology Congress
|
(Merck KGaA)
|
(Invalid Date)
|
| Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
|
(Bristol-Myers Squibb)
|
(Invalid Date)
|
| Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
|
(Eli Lilly)
|
(Invalid Date)
|
| New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
|
(Eli Lilly)
|
(Invalid Date)
|
| New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Duloxetine
|
(Boehringer Ingelheim)
|
(Invalid Date)
|
| Ranbaxy Introducing Osteoporosis Drug EVISTA® into the Romanian Market
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of EVISTA in Romania
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Daiichi Sankyo and Ranbaxy Leverage New Business Model With Launch of Evista in Romania
|
(Ranbaxy Laboratories)
|
(Invalid Date)
|
| Brilinta data soothes some patent cliff woes for Astra
|
(AstraZeneca)
|
(Invalid Date)
|
| Dyax Announces Developments in Licensing and Funded Research Program
|
(Dyax)
|
(Invalid Date)
|
| The Medicines Company Withdraws European Marketing Application for 3-7 Day Daily Dose Oritavancin Therapy
|
(The Medicines Company)
|
(Invalid Date)
|
| Pharmacoeconomic Analysis of Reported Use of ENTEREG(R) (alvimopan) Published in American Journal of Health-System Pharmacy
|
(Adolor)
|
(Invalid Date)
|
| Event – Astra hoping to shine with full Brilinta data
|
(AstraZeneca)
|
(Invalid Date)
|
| Lilly admits defeat over arzoxifene
|
(Eli Lilly)
|
(Invalid Date)
|
| Lilly Reports on Outcome of Phase III Study of Arzoxifene
|
(Eli Lilly)
|
(Invalid Date)
|
| Effient(TM) is Now Available in Pharmacies
|
(Eli Lilly)
|
(Invalid Date)
|
| Effient(TM) is Now Available in Pharmacies
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Merck KGaA Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLC
|
(Merck KGaA)
|
(Invalid Date)
|
| Merck KGaA Has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung Cancer
|
(Merck KGaA)
|
(Invalid Date)
|
| Therapeutic focus - AstraZeneca makes rare advance with sepsis treatment
|
(AstraZeneca)
|
(Invalid Date)
|
| Clinical Trial by Licensee Does Not Meet Primary Endpoint
|
(AutoImmune)
|
(Invalid Date)
|
| No happy ever after for BioMS
|
(BioMS Medical)
|
(Invalid Date)
|
| Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial
|
(BioMS Medical)
|
(Invalid Date)
|
| Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
|
(Eli Lilly)
|
(Invalid Date)
|
| Europe takes surprisingly tough line with Erbitux in lung cancer
|
(Merck KGaA)
|
(Invalid Date)
|
| Merck KGaA Considers Appealing CHMP Opinion on Erbitux Treatment for Non-Small Cell Lung Cancer
|
(Merck KGaA)
|
(Invalid Date)
|
| FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis First and Only FDA-approved Anabolic Agent in the U.S. Now Indicated to Treat the Leading Type of Secondary Osteoporosis
|
(Eli Lilly)
|
(Invalid Date)
|
| Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 Study
|
(Alkermes)
|
(Invalid Date)
|
| Event – Vectibix data could threaten Erbitux
|
(Amgen)
|
(Invalid Date)
|
| ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 Study
|
(Eli Lilly)
|
(Invalid Date)
|
| ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
|
(Bristol-Myers Squibb)
|
(Invalid Date)
|
| Therapeutic focus - Shire's Intuniv could grab attention in ADHD market
|
(Shire)
|
(Invalid Date)
|
| Lilly and Daiichi finally celebrate Effient approval
|
(Eli Lilly)
|
(Invalid Date)
|
| Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
|
(Eli Lilly)
|
(Invalid Date)
|
| ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
|
(Eli Lilly)
|
(Invalid Date)
|
| Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(™)
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
|
(Alkermes)
|
(Invalid Date)
|
| New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
|
(Eli Lilly)
|
(Invalid Date)
|
| Lilly Receives Fourth FDA Approval for ALIMTA(R) (Pemetrexed for Injection)
|
(Eli Lilly)
|
(Invalid Date)
|
| MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
|
(MacroGenics)
|
(Invalid Date)
|
| FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
|
(Eli Lilly)
|
(Invalid Date)
|
| Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
|
(United Therapeutics)
|
(Invalid Date)
|
| Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
|
(Eli Lilly)
|
(Invalid Date)
|
| Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years
|
(Eli Lilly)
|
(Invalid Date)
|
| Interim Study Results Presented at ADA 2009
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Interim Study Results Presented at ADA 2009
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
|
(Eli Lilly)
|
(Invalid Date)
|
| ASCO - New lung cancer treatment strategy has sceptics as well as fans
|
(Eli Lilly)
|
(Invalid Date)
|
| Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
|
(Eli Lilly)
|
(Invalid Date)
|
| Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
|
(Isis Pharmaceuticals)
|
(Invalid Date)
|
| Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
|
(Eli Lilly)
|
(Invalid Date)
|
| Merck KGaA at Forefront of Exploring Markers of Response in Continued Effort to Personalize Cancer Care
|
(Merck KGaA)
|
(Invalid Date)
|
| ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
|
(Eli Lilly)
|
(Invalid Date)
|
| FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
|
(United Therapeutics)
|
(Invalid Date)
|
| Lilly advances its quest for Alzheimer's holy grail
|
(Eli Lilly)
|
(Invalid Date)
|
| Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
|
(Eli Lilly)
|
(Invalid Date)
|
| Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
|
(Eli Lilly)
|
(Invalid Date)
|
| Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| EVISTA® Improves Patient Compliance in Osteoporosis Management
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Event - United Therapeutics could score double approval
|
(United Therapeutics)
|
(Invalid Date)
|
| Olanzapine Long-Acting Injection (LAI) Efficacy and Safety Data Presented at American Psychiatric Association Annual Meeting
|
(Eli Lilly)
|
(Invalid Date)
|
| CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
|
(Implicit Bioscience)
|
(Invalid Date)
|
| Therapeutic focus - Real innovation in antipsychotics is on distant horizon
|
(Vanda Pharmaceuticals)
|
(Invalid Date)
|
| Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples
|
(Eli Lilly)
|
(Invalid Date)
|
| Anthera’s Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
|
(Anthera Pharmaceuticals)
|
(Invalid Date)
|
| New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
|
(Alkermes)
|
(Invalid Date)
|
| New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
|
(Eli Lilly)
|
(Invalid Date)
|
| New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir
|
(Vertex Pharmaceuticals)
|
(Invalid Date)
|
| Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
|
(Eli Lilly)
|
(Invalid Date)
|
| Telaprevir Data Presented at EASL Show Unprcedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study
|
(Vertex Pharmaceuticals)
|
(Invalid Date)
|
| New Data On Tibotec Investigational Hepatitis C Compounds Being Presented At EASL
|
(Johnson & Johnson)
|
(Invalid Date)
|
| BioMS Medical's Pivotal International Multiple Sclerosis Trial Receives Positive Review From Data Safety Monitoring Board
|
(BioMS Medical)
|
(Invalid Date)
|
| BioMS Medical's Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review From Data Safety Monitoring Board
|
(BioMS Medical)
|
(Invalid Date)
|
| Lilly’s positive arzoxifene data tinged with disappointment
|
(Eli Lilly)
|
(Invalid Date)
|
| First Launch of Efient® Worldwide Takes Place in the UK
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
|
(Alkermes)
|
(Invalid Date)
|
| Following Encouraging Results Anthera to Continue Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
|
(Anthera Pharmaceuticals)
|
(Invalid Date)
|
| Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista® (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
|
(Eli Lilly)
|
(Invalid Date)
|
| FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
|
(Eli Lilly)
|
(Invalid Date)
|
| Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
|
(Transition Therapeutics)
|
(Invalid Date)
|
| Aurobindo Pharma Receives Final Approval for Fluoxetine Oral Solution
|
(Aurobindo Pharma)
|
(Invalid Date)
|
| Actavis Launches Gemcitabine on Patent Expiry in EU Markets
|
(Actavis)
|
(Invalid Date)
|
| ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX® in U.S.
|
(Eli Lilly)
|
(Invalid Date)
|
| European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
|
(Eli Lilly)
|
(Invalid Date)
|
| European Commission Approves EFIENT® (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Which of 2009's launches will be future blockbusters?
|
(Amgen)
|
(Invalid Date)
|
